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Abstract 
Background: Nanoscale drug‑delivery systems (DDSs) have great promise in tumor diagnosis and treatment. Platelet 
membrane (PLTM) biomimetic DDSs are expected to enhance retention in vivo and escape uptake by macrophages, 
as well as minimizing immunogenicity, attributing to the CD47 protein in PLTM sends “don’t eat me” signals to mac‑
rophages. In addition, P‑selectin is overexpressed on the PLTM, which would allow a PLTM‑biomimetic DDS to specifi‑
cally bind to the CD44 receptors upregulated on the surface of cancer cells.
Results: In this study, porous nanoparticles loaded with the anti‑cancer drug bufalin (Bu) were prepared from 
a chitosan oligosaccharide (CS)‑poly(lactic‑co‑glycolic acid) (PLGA) copolymer. These were subsequently coated 
with platelet membrane (PLTM) to form PLTM‑CS‑pPLGA/Bu NPs. The PLTM‑CS‑pPLGA/Bu NPs bear a particle size 
of ~ 192 nm, and present the same surface proteins as the PLTM. Confocal microscopy and flow cytometry results 
revealed a greater uptake of PLTM‑CS‑pPLGA/Bu NPs than uncoated CS‑pPLGA/Bu NPs, as a result of the targeted 
binding of P‑selectin on the surface of the PLTM to the CD44 receptors of H22 hepatoma cells. In vivo biodistribution 
studies in H22‑tumor carrying mice revealed that the PLTM‑CS‑pPLGA NPs accumulated in the tumor, because of a 
combination of active targeting effect and the EPR effect. The PLTM‑CS‑pPLGA/Bu NPs led to more effective tumor 
growth inhibition over other bufalin formulations.
Conclusions: Platelet membrane biomimetic nanoparticles played a promising targeted treatment of cancer with 
low side effect.
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Background
Nanoscale drug-delivery systems (DDSs) including inor-
ganic nanoparticles [1, 2], liposomes [3, 4], hydrogels 
[5–7], and polymeric nanoparticles [8, 9] (among oth-
ers) have great promise in tumor diagnosis and treat-
ment. There are often problems with biocompatibility 
and short systemic circulation times when using these 
however, and much recent work has focused on using 
surface modifiers such as poly(ethylene glycol) (PEG) 
and proteins to ameliorate these issues [10–12]. Unfortu-
nately, such PEG or protein modification can also impede 
the uptake of a DDS by cancer cells [13, 14]. Moreover, 
simple surface functionalization approaches are unable to 
precisely mimic the complex interfaces present in nature, 
and ultimately cannot completely vitiate recognition as a 
foreign body and the subsequent immune response [15, 
16].
To overcome this hurdle to clinical translation, cell 
membrane cloaking has recently attracted signifi-
cant attention as a route to endow nanoparticles with 
enhanced biocompatibility, low immunogenicity and 
active targeting abilities [17, 18]. Gao et al. [19] designed 
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a set of nanoparticles (NPs) by encapsulating perfluoro-
carbon within the biocompatible polymer poly(lactic-
co-glycolic acid) (PLGA), followed by coating with a red 
blood cell membrane (RBCM). These NPs were able to 
prolong the circulation time in the blood compared to 
uncoated particles, as well providing efficient intratumor 
penetration. The latter was attributed to the CD47 pro-
tein on the RBCM regulating phagocytic uptake by mac-
rophages through interactions with SIRPα. In other work, 
Martinez et al. [20] designed leukocyte-based biomimetic 
nanoparticles as a novel theranostic platform for inflam-
matory diseases, and demonstrated that their materials 
have the ability to target the activated vasculature and 
exhibit superior accumulation in tumors and vascular 
lesions.
Platelets are components of the blood which exist to 
help prevent bleeding after blood vessel injuries. They 
avoid phagocytic uptake by macrophages, target and 
adhere to injured parts of the vasculature, and display 
enhanced binding to platelet-adhering pathogens [15]. 
Platelet membrane (PLTM) biomimetic DDSs thus are 
expected to enhance retention in vivo and escape uptake 
by macrophages, as well as minimizing immunogenicity 
as a result of the CD47 membrane protein sending “don’t 
eat me” signals to macrophages [21, 22]. In addition, 
P-selectin is overexpressed on the PLTM, which would 
allow a PLTM-biomimetic DDS to specifically bind to 
the CD44 receptors upregulated on the surface of cancer 
cells [23].
Here, we explored a strategy utilizing the PLTM 
to develop biomimetic nanoparticles with the aim of 
achieving enhanced biocompatibility and active cancer 
targeting. Poly(lactic-co-glycolic acid) (PLGA) nano-
particles were developed to deliver bufalin, an active 
ingredient which exhibits strong antineoplastic activi-
ties, including reversing multi-drug resistance, inhib-
iting cancer angiogenesis and regulating the immune 
response by inhibiting  Na+,  K+-ATPase [24, 25]. More-
over, bufalin is involved in complex cell-signal trans-
duction pathways and results in selective control of 
tumor but not normal cellular proliferation [26, 27]. 
Typically, their long degradation times (weeks or even 
months) causes PLGA systems to release their drug 
cargo rather slowly, which limits the use of PLGA NPs 
in this setting [28]. However, the use of pore-forming 
agents such as Vitamin E polyethylene glycol succinate 
(TPGS) to prepare porous PLGA NPs can overcome 
this problem [29]. As displayed in Scheme  1, biode-
gradable PLGA was firstly conjugated to chitosan oli-
gosaccharide (CS), followed by self-assembly with the 
porogen TPGS and bufalin by the nanoprecipitation 
method, resulting in porous bufalin-loaded nanoparti-
cles (CS-pPLGA/Bu NPs) with positive surface charges. 
These were functionalized by absorbing the negatively 
charged PLTM by layer-by-layer (L-B-L) self-assembly, 
and the therapeutic effects of the NPs were explored in 
a murine tumor model.
Materials and methods
Materials
PLGA (lactide:glycolide 50:50, Mw ~ 21,000) was pur-
chased from Jinan Daigang Biomaterials Co., Ltd. 
Chitosan oligosaccharide (pharmaceutical grade, 
Mw ~ 1200) was procured from Shanghai Xinxi Bio-
Tech Co., Ltd, and bufalin from the Baoji Herbest 
Bio-Tech Co., Ltd. N-hydroxysuccinimide (NHS), 
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydro-
chloride (EDC·HCl), dicyclohexylcarbodiimide (DCC), 
fluoresceinisothiocyanate (FITC), Hoechst 33342, and 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbro-
mide (MTT) were acquired from Sigma-Aldrich. Vitamin 
E TPGS and cyanine-5,5–carboxylic acid (Cy5.5–COOH, 
purity 99%) were obtained from J&K Scientific Ltd. H22 
cells (a mouse hepatocellular carcinoma cell line) and 
RAW 264.7 (macrophage-like) cells were sourced from 
the Institute of Biochemistry and Cell Biology of the 
Chinese Academy of Sciences. A membrane protein 
extraction kit and protease inhibitor were procured from 
Phygene Life Sciences Co., Ltd. A Pierce BCA protein 
assay kit was procured from Life Technologies Co., Ltd. 
Mouse P-selectin protein (purity > 95%) was obtained 
from R&D Systems. Mouse anti-human CD41, mouse 
anti-human CD47, P-selectin antibody, DMEM medium, 
fetal bovine serum (FBS), phosphate buffered saline 
(PBS), penicillin and streptomycin were purchased from 
the Shanghai Bionove-gene Biomedical Technology Co., 
Ltd. All other chemicals were reagent grade and used as 
received.
Synthesis of CS‑PLGA copolymer
The CS conjugated PLGA copolymer was synthesized 
by an EDC coupling method. Briefly, PLGA (105  mg, 
5  μmol) was dissolved in 10.0  mL of dimethyl forma-
mide (DMF) and preactivated using EDC·HCl (2.9  mg, 
15 μmol) and NHS (1.7 mg, 15 μmol) for 0.5 h in an ice 
bath. The temperature was allowed to rise to room tem-
perature, after which 9  mg (7.5  μmol) of water-soluble 
CS was added and the reaction incubated under stirring 
for 48 h at room temperature, under an  N2 stream. Any 
residual reactive agents and byproducts were removed 
by dialysis (MWCO 7000  Da) against deionized water 
for 2 days. The final product was collected after lyophi-
lization, followed by 1H NMR analysis with a Bruker 
Advance 400 MHz spectrometer.
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Preparation and characterization of CS‑pPLGA/Bu NPs
The preparation of bufalin-loaded porous CS-PLGA 
nanoparticles (CS-pPLGA/Bu NPs) was achieved fol-
lowing a literature nanoprecipitation method with 
some modifications [29]. 20  mg of CS-PLGA, 4  mg of 
TPGS and varied amounts of bufalin (CS-PLGA: bufa-
lin ratio = 20:1, 10:1 or 5:1 w/w) were dissolved in 2 mL 
acetone, and the resultant solution then added drop-
wise to 10  mL of deionized water. The mixture was 
stirred at 1000 rpm in air for 3 h and then placed under 
vacuum for 12  h to evaporate any residual acetone. 
2 mL of the resulting nanoparticles set aside for parti-
cle size and zeta potential measurements. The remain-
der of the dispersion was centrifuged and washed three 
times with deionized water to create porous nanoparti-
cles. The supernatant was collected and tenfold diluted 
with methanol and a UV spectrophotometer at 298 nm 
(λmax of bufalin) used to quantify the bufalin loading. 
The bufalin concentration was determined with refer-
ence to a pre-determined calibration curve. The bufalin 
Scheme 1 a Illustration of the preparation route to PLTM‑CS‑pPLGA/Bu NPs; b in vivo targeted bufalin delivery to a tumor site mediated by binding 
of P‑selectin on the surface of the PLTM to CD44 receptors of the tumor cells
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encapsulation efficiency (EE %) and loading content 
(LC %) were determined as follows:
Bufalin-loaded non-porous CS-PLGA nanoparti-
cles (CS-PLGA/Bu NPs) were prepared using the same 
method as above, except that TPGS was not added. Simi-
larly, CS-pPLGA NPs without bufalin were generated fol-
lowing the same protocol but with no bufalin included in 
the preparation process. All the NP samples were stored 
at 4  °C until further use. For surface area and pore size 
measurements, a dry CS-pPLGA NPs powder were pre-
pared after freeze drying. Measurements were performed 
on an automated area and pore size analyzer (Quan-
tachrome, Autosorb-iQ).
Preparation of PLTM
PLTM was obtained according to the manufacture’s 
instruction. The anti-coagulated whole blood of mice was 
added to centrifuge tubes above a separating medium 
layer (mice peripheral blood platelet separation medium, 
Tianjin Haoyang Bio-Tech Co., Ltd). The samples were 
centrifuged at 250–300  g for 15  min at room tempera-
ture. The supernatant comprised a platelet rich plasma 
(PRP). The PRP was diluted with an equal volume of sam-
ple diluent, followed by centrifuging at 500 g for 20 min. 
Platelets were obtained after washing the precipitate with 
phosphate buffered saline (PBS) buffer three times, and 
then resuspended in PBS containing 1  mM EDTA and 
2 mM of protease inhibitor. The morphology of the plate-
lets was assessed using an optical microscope (Nikon 
Eclipse E400). The platelet membrane was subsequently 
obtained by a freeze–thaw process assisted by sonication 
[15]. Platelet suspensions were frozen at − 80  °C before 
being thawed to room temperature; this process was 
repeated three times. Next, centrifugation at 4000  g for 
3  min was employed to isolate the platelet membranes. 
The pellets were suspended in PBS buffer containing 
2  mM of protease inhibitor and sonicated for 5  min at 
40 kHz and a power of 100 W, resulting in a suspension 
of platelet membrane fragments.
Preparation and characterization of PLTM biomimetic 
CS‑pPLGA/Bu NPs
To coat PLTM onto CS-pPLGA/Bu NPs, 2 mL PBS con-
taining 4 mg nanoparticles was mixed with PLTM frag-
ments derived from 5  mL of whole blood. The mixture 
underwent sonication at 40 kHz and a power of 100 W 
for 5  min, followed by being extruded repeatedly (11 
EE% =
mass of bufalin in NPs
total mass of bufalin in feed
× 100%
LC% =
mass of bufalin in NPs
total mass of NPs
× 100%.
times) through a 200  nm porous membrane using a 
mini extruder (LiposoFast-Basic, Avanti). This resulted 
in PLTM-CS-pPLGA/Bu NPs. Zeta potential and par-
ticle size were measured at a concentration of 2 mg/mL 
by DLS (BI-200SM, Brookhaven Instruments), and the 
morphology was characterized using a transmission elec-
tron microscope (TEM; JEOL 2010F instrument). The 
size distribution of the CS-pPLGA/Bu NPs and PLTM-
CS-pPLGA/Bu NPs was calculated from the analysis 
of around 100 nanoparticles in TEM images, using the 
Image J software. Blank PLTM-CS-pPLGA NPs were 
similarly prepared from the drug-free CS-pPLGA NPs.
Western blotting
Western blotting was used to examine the platelet mem-
brane proteins, following a reported procedure with 
some modifications [30]. Briefly, CS-pPLGA/Bu NPs and 
PLTM-CS-pPLGA/Bu NPs were normalized to equiva-
lent overall protein concentrations using a Pierce BCA 
protein assay kit. The membrane proteins were extracted 
using a specific membrane protein extraction kit. 60 μL 
of the resultant buffered solution was used for sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) on a 10% SDS-PAGE gel at 100  V, the proteins 
were then transferred using a semi-dry transfer method 
to a polyvinylidene difluoride (PVDF) membrane, fol-
lowed by bathing in 5% skimmed milk (20  mL) for 2  h. 
Key platelet membrane proteins were identified using 
mouse anti-human CD41, mouse anti-human CD47, and 
P-selectin antibodies. The membranes were stored over-
night at 4  °C and then washed with 50 mL of PBS con-
taining 0.05% v/v Tween 20 before the addition of goat 
anti-rat HRP-conjugated secondary antibodies and incu-
bation for another 2  h at room temperature. The mem-
branes were combined with 1 mL of the ECL luminescent 
reagent followed by scanning (Epson Perfection V370 
Photo, Seiko Epson Corporation) and imaging within the 
ImageJ software (National Institutes of Health) to quan-
tify the amount of proteins present.
In vitro drug release
The drug release profiles of CS-PLGA/Bu, CS-pPLGA/
Bu and PLTM-CS-pPLGA/Bu NPs were evaluated by 
resuspending the NPs in PBS, and employing a dialysis 
method. 2  mL of a CS-pPLGA/Bu, CS-pPLGA/Bu or 
PLTM-CS-pPLGA/Bu NP water suspension (2  mg/mL) 
was loaded into a dialysis bag (MWCO = 7000  Da) and 
immersed in 18  mL of a release buffer (PBS containing 
0.1% w/v Tween 80, pH 5.5 or 7.4). All experiments were 
performed at 37  °C with shaking (120 rpm) for 48 h. At 
predetermined time points, 1 mL of the external medium 
was collected and replaced with an equal volume of fresh 
pre-heated medium. The concentration of bufalin in the 
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release medium was quantified by UV spectroscopy at 
298 nm. Data are reported as mean ± standard deviation 
(SD), n = 3.
MTT assays
The in vitro cytotoxicity of blank PLTM-CS-pPLGA NPs 
was studied to evaluate their cytocompatibility. H22 cells 
were maintained in DMEM medium supplemented with 
1% penicillin, 1% streptomycin, and 10% v/v fetal bovine 
serum. The cells were cultured as a monolayer at 37 °C in 
a humidified atmosphere containing 5%  CO2. For viability 
experiments, 200 μL of H22 cells were seeded into each 
well of 96-well plates at a density of 8 × 103  cells/well. 
After overnight incubation at 37  °C in a humidified 5% 
 CO2 environment, the medium was removed and 200 μL 
of fresh medium containing different concentrations 
of blank PLTM-CS-pPLGA NPs (1, 10, 25, 50, 100, 250 
and 500 μg/mL) was added. After incubation for another 
24  h, 20  μL of MTT solution (10  μg/mL) was added to 
the wells, and the plates incubated for an additional 4 h. 
After this, the medium was carefully removed, 200 μL of 
DMSO added to each well to dissolve the MTT-formazan 
generated by live cells, and the plate thoroughly shaken 
for 15 min. The absorbance of the wells was finally meas-
ured at 570 nm, using a microplate reader (Multiskan FC, 
Thermo Scientific).
The anticancer efficacy of the drug-loaded formula-
tions was investigated following a similar protocol as 
described above, except that media containing free bufa-
lin, CS-pPLGA/Bu NPs and PLTM-CS-pPLGA/Bu NPs 
(concentration of bufalin: 0.1, 0.5, 1, 5, 10, 20  μg/mL) 
was added after the initial incubation. Data are reported 
as mean ± SD, with three independent experiments each 
containing three replicates having been performed.
Cellular uptake evaluation
In order to track the distribution of the PLTM-CS-
pPLGA NPs visually in cells, we used FITC to label the 
CS-PLGA. Briefly, CS-PLGA (222  mg, 0.01  mmol) and 
FITC (19.5  mg, 0.05  mmol) were dissolved in 10  mL of 
dichloromethane, before being stirred for 12  h in the 
dark at 4  °C. The dichloromethane was removed by 
rotary evaporation, and 5 mL dimethyl formamide added 
to dissolve the product. This was followed by dialysis 
against 1 L of deionized water for 3 days (7000 Da Spec-
tra/Por dialysis tube). Finally, the sample was freeze-dried 
for 48  h to obtain dry FITC labeled CS-PLGA. FITC 
labeled NPs (FITC-CS-pPLGA NPs and FITC-PLTM-CS-
pPLGA NPs) were prepared using the same protocols as 
described above.
For cellular uptake evaluation, 200 µL of H22 cells or 
RAW 264.7 cells were seeded onto sterile coverslips 
placed in each well of a 24-well culture plate (5 × 104 cells 
per well). 800 µL of DMEM supplemented with 1% peni-
cillin, 1% streptomycin, and 10% v/v fetal bovine serum 
was added to each well. After incubation for 24  h, the 
medium was aspirated and replaced by 450 μL of fresh 
medium. 50 μL of PBS suspensions of FITC-CS-pPLGA 
or FITC-PLTM-CS-pPLGA NPs (1 mg/mL) were added. 
Following a further incubation step for 2  h (37  °C; 5% 
 CO2), the culture medium was removed and the cells 
rinsed three times with PBS. They were then fixed with 
4% paraformaldehyde for 20  min at 4  °C, and washed 
with PBS three times. The cell nuclei were stained with 
0.5 mL of Hoechst 33342 (10 μg/mL) for 15 min at 37 °C 
and washed three times with PBS. Finally, the cells were 
studied using a confocal laser-scanning microscope 
(CLSM, Carl Zeiss LSM 700) with an argon blue laser 
light at 488 nm and a magnification of 63×. Each experi-
ment was conducted in triplicate, and representative 
images are shown. For the blocking experiments, H22 
cells were pre-incubated with free P-selectin (20 μg/mL) 
for 1 h. After removing the free P-selectin, the cells were 
incubated with FITC-PLTM-CS-pPLGA NPs (1 mg/mL) 
for another 2 h. The cells were then treated and imaged as 
described above.
Flow cytometry
Flow cytometry was used to quantify NP uptake by H22 
cells. 100 μL of H22 cells were cultured in six-well plates 
(1 × 106  cells/well) for 24  h. 200  μL of PBS containing 
FITC-CS-pPLGA or FITC-PLTM-CS-pPLGA NP (1 mg/
mL) were added to each well. After incubation at 37  °C 
for 4 h, the cells were digested by 0.25% w/v trypsin and 
0.03% w/v EDTA and centrifuged at 1000 rpm for 5 min. 
The supernatant culture medium was discarded, and the 
precipitate dispersed in 500 μL of PBS and incubated for 
15  min in the dark. Finally, cellular uptake was deter-
mined by flow cytometry using a Becton–Dickinson 
FACScan analyzer (Frankin, CA). A blocking experiment 
was also performed to evaluate the active targeting effect 
mediated by selective blinding between P-selectin and 
the CD44 receptor. H22 cells were first pre-incubated 
with free P-selectin (20  μg/mL) for 1  h, after which the 
free P-selectin was removed and the cells incubated with 
FITC-PLTM-CS-pPLGA NPs (1 mg/mL) for another 4 h 
at 37 °C. Cellular uptake was then probed by flow cytom-
etry as detailed above.
Hemocompatibility assay
Fresh blood was obtained from a healthy ICR mouse 
and centrifugation performed at 3000  rpm for 5 min to 
obtain red blood cells (RBCs). The RBCs were washed 
three times using PBS (pH 7.4), and then treated with 
equal amounts of PBS (negative control), Triton X-100 
(positive control) and a 500  μg/mL suspension of 
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PLTM-CS-pPLGA NPs in PBS. The samples were incu-
bated at 37 °C for 1 h and centrifugation was performed 
at 5000 rpm for 10 min. 100 μL of the supernatant from 
each tube carefully collected and added to each well of 
96-well plates in triplicate. The absorbance of each well 
was obtained at 540 nm in a microplate reader (Multis-
kan FC, Thermo Scientific) and the formula below used 
to calculate the percentage of RBC hemolysis [31]. The 
whole procedure was performed three times.
Tumor model mice
All animal experiments were undertaken following 
robust ethical review and in accordance with the pro-
cedures authorized by the Committee for Experimen-
tal Animal Welfare and Ethics of Yunnan University of 
Traditional Chinese Medicine. ICR female mice (spe-
cific pathogen-free grade, 18–20  g) were procured 
from Jiangsu KeyGENBioTECH Co. Ltd, and tumors 
implanted by subcutaneous injection of 1 × 106 H22 cells 
in 100 μL of PBS (pH = 7.2–7.4) into the right front limb 
armpit of each mouse. Tumor volume was calculated as 
 width2 × length/2.
In vivo and ex vivo imaging
In vivo fluorescence imaging was performed using an 
IVIS Lumina LT imaging system (Caliper Life Sciences) 
to investigate the biodistribution of Cy5.5 labeled PLTM-
CS-pPLGA NPs. The latter were prepared according 
to the literature [32], with some modifications. 6  mg of 
Cy5.5–COOH was dissolved in 1  mL DCM contain-
ing 2.2  mg DCC, and placed for 30  min in an ice bath. 
6.5 mL of a DCM solution containing 320 mg CS-PLGA 
and 1.3 mg DMAP was then added into the above solu-
tion, and the two allowed to react under gentle stirring 
in the dark overnight. Next, the solvent was evaporated 
using a rotary evaporator. Unreacted Cy5.5–COOH was 
removed by washing with ice-cold methanol and recov-
ery of the solid product by centrifugation at 5000  rpm. 
The washing process was repeated three times, resulting 
in Cy5.5-CS-PLGA. This was then processed into nano-
particles using the same procedures as described above.
200 μL of Cy5.5 labeled bufalin-free PLTM-CS-pPLGA 
NPs or Cy5.5 labeled CS-pPLGA NPs in PBS (2 mg/mL) 
were i.v. injected into each mouse when the tumor vol-
ume reached 200  mm3. Fluorescent imaging at various 
time intervals after the injection was performed using a 
60 s exposure time, with excitation at 748 nm and emis-
sion at 780 nm. For ex vivo imaging, H22 tumor-bearing 
Hemolysis % = OD[test]− OD[negative control]
× 100/OD[positive control]
mice were sacrificed by cervical vertebra dislocation 6 h 
after i.v. injection with the Cy5.5 labeled NPs. The tumor 
and major organs were collected and imaged using the 
IVIS Lumina LT imaging system.
Immunofluorescence assay
To further evaluate the targeted effect of PLTM biomi-
metic NPs to tumor through recognizing CD44 receptor 
on tumor cells, tumors from mice after treating PLTM 
coated or uncoated Cy5.5 labeled CS-pPLGA/Bu NPs for 
24  h were sectioned into 100  μm sections under frozen 
conditions. The tumor tissues were fixated with para-
formaldehyde, and then incubated with primary antibody 
(rat anti-mouse CD44, Servicebio) against CD44 at 4  °C 
overnight followed by the incubation with secondary 
antibody (goat anti-rat IgG, DyLight 488, Servicebio) at 
37 °C for 50 min. The nuclei of the cells were stained with 
DAPI. The obtained slices were scanned by an imaging 
system (Nikon DS-U3).
In vivo antitumor efficacy
Mice bearing H22 tumors were treated after their tumors 
reached approximately 120  mm3 in size. The mice were 
randomly divided into four groups (5 mice per group) 
and given 200 μL of PBS, free bufalin, CS-pPLGA/Bu 
NPs, or PLTM-CS-pPLGA/Bu NPs (bufalin dose: 2 mg/
kg) intravenously every 2  days. Tumor sizes and body 
weights were monitored and recorded every 2  days for 
16  days, after which the experiment was halted. After 
this time, the mice were sacrificed by cervical vertebra 
dislocation. The tumors and major organs of each group 
were extracted. The tissues were fixed with 4% para-
formaldehyde solution and embedded in paraffin. 4 mm 
slices were taken, mounted on glass slides, stained by 
hematoxylin and eosin (H&E), and imaged with a digital 
microscope (Nikon DS-U3 microscope). The tumors tis-
sues were further stained with terminal deoxynucleotidyl 
transferase UTP nick end labeling (TUNEL) to study the 
extent of apoptosis in the tumors.
Toxicity
In order to exclude PLTM effects on tumor growth 
inhibition and evaluate the biosafety after the admin-
istration of PLTM-CS-pPLGA NPs, mice bearing H22 
tumors (~ 120 mm3 in size) were randomly divided into 
two groups (5 mice per group) and given 200 μL of PBS 
or a suspension of the PLTM-CS-pPLGA NPs (at the 
same dose as the therapeutic group) intravenously every 
2 days. Tumor sizes were monitored and recorded every 
2 days for 16 days. On day 16, 0.5 mL of blood was with-
drawn for blood biochemistry analysis. The blood sam-
ples were centrifuged at 3500  rpm for 15  min at 4  °C 
to obtain serum. The serum concentrations of alanine 
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aminotransferase (ALT), aspartate aminotransferase 
(AST), creatinine (CREA) and urea nitrogen (BUN) were 
then analyzed using an automatic biochemistry analyzer 
(7600, Hitachi). The liver and kidney were removed for 
histological assessment by H&E staining.
Statistical analysis
Differences between two groups were analyzed by Stu-
dent’s t test and mean values were compared via one-way 
ANOVA; The significance level was defined as P < 0.05, 
and the data were marked with (*) P < 0.05, (**) P < 0.005 
and (***) P < 0.001.
Results and discussion
Synthesis and characterization of CS‑PLGA
In order to construct nanoparticles with a positive sur-
face charge for absorbing negative charged PLTM by 
L-B-L assembly, a water-soluble chitosan oligosaccha-
ride was initially conjugated to PLGA. 1H-NMR spectra 
(Additional file  1: Figure S1) showed that a new reso-
nance peaks at δ = 7.9(m) appeared after the conjugation. 
This can be ascribed to the amide bond (–CO–NH–). 
All other hydrogen signals from CS and PLGA are also 
visible in the CS-PLGA spectrum, demonstrating suc-
cessful conjugation. Zeta potential data confirmed this. 
When the carrier phase pH was adjusted from 8.6 to 5.0, 
the zeta potential of CS-PLGA went from a negative to 
a positive value (Additional file  1: Figure S2), ascribed 
to the increased protonation of the CS segments under 
acidic conditions. In contrast, the zeta potential of CS 
and PLGA show much more modest changes in response 
to pH variation; CS has an increasingly negative zeta 
potential as the pH goes up, while PLGA becomes less 
positively charged.
Preparation of PLTM‑coated biomimetic NPs
The pore forming agent TPGS was used generate porous 
CS-PLGA particles. TEM images (Fig. 1a) show that CS-
PLGA/Bu NPs show a core/shell morphology. The core 
manifests as a dark area surrounded by a lighter grey 
CS shell, and the particles have a mean size of ~ 170 nm 
(Fig.  1b). The small size of these particles means that 
the porosity cannot be seen. In order to ensure that the 
TPGS did indeed generate pores in the formulations, 
Fig. 1 Characterization date on the CS‑pPLGA/Bu NPs: a a TEM image, b the particle size distribution and c a FESEM image, and the 
PLTM‑CS‑pPLGA/Bu NPs: d a TEM image, e the particle size distribution and f a FESEM image
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larger particles were prepared with a low stirring speed; 
surface pores can be clearly observed in these (Fig.  1c), 
demonstrating that TPGS can serve as a pore-forming 
agent. Brunauer–Emmett–Teller (BET) measurements 
showed that the surface area and average pore diameter 
of CS-pPLGA NPs were 11.65 m2 g−1 and 3.05 nm (Addi-
tional file 1: Figure S3), further confirming the porosity of 
the nanoparticles.
Platelets (PLTs) were successfully extracted from fresh 
whole blood (Additional file  1: Figure S4) by gradient 
centrifugation, and then subjected to repeated freeze–
thaw process to obtain the empty platelets. After PLTM 
coating by sonicating and extruding the mixture of CS-
pPLGA NPs and empty platelets, a cell-membrane struc-
ture can be clearly observed around the CS-pPLGA NPs, 
with an outer shell ≈ 15 nm in thickness (Fig. 1d), and the 
particles have a mean size of ~ 192 nm (Fig. 1e). FESEM 
images of PLTM-CS-pPLGA NPs (Fig.  1f ) also dem-
onstrate the nanoparticles to be wrapped by an exter-
nal layer. The zeta potential of the nanoparticles after 
PLTM coating decreased to ~ − 28 mV (cf. ~ − 5 mV for 
CS-PLGA; Additional file  1: Figure S5); the PLTM-CS-
pPLGA NPs thus possess the same surface charge as the 
PLTM, consistent with the existence of the latter on the 
surface of the NPs.
The hydrodynamic particle size of the two NPs and 
the colloid stability of the PLTM-CS-pPLGA/Bu NPs in 
water, PBS and cell culture medium were quantified by 
DLS. The results are presented in Fig.  2. The mean size 
of all the NPs lies between 150 and 195  nm, and their 
polydispersities are low (Fig.  2a). The coated PLTM-
CS-pPLGA/Bu NPs exhibited high colloidal stability 
and could be dispersed in different physiological buffers 
without aggregation over time (Fig. 2b); this is attributed 
to the stabilizing effect played by the plasma membrane’s 
hydrophilic surface glycans [33].
Platelet membrane proteins
The presence of key platelet membrane proteins, includ-
ing the platelet-specific CD41, immunomodulatory 
CD47, and the cancer-targeted P-selectin on the nano-
particles was examined by Western blotting. It was 
observed that the PLTM-CS-pPLGA NPs have an exte-
rior protein environment very similar to the platelet 
membrane source (Additional file 1: Figure S6).
Drug loading and release behavior
The results of encapsulation efficiency and loading con-
tent of the bufalin-loaded porous CS-pPLGA NPs are 
summarized in Additional file  1: Table  S1. Although, 
the highest LC (11.5 ± 2.1%) was achieved when the 
mass ratio of Bu: CS-PLGA was 1:5, the EE was only 
65.4 ± 4.2%, leading to wastage of bufalin. When the ratio 
reached to 1:20, the low LC (only 4.6 ± 1.3%) rendered the 
NPs non-viable for further exploitation. The 1:10 ratio 
offers a good balance between these two extremes, with 
an LC and EE of 8.5 ± 1.9% and 92.8 ± 3.5%, respectively.
Drug release data in PBS at pH 7.4 and pH 5.5 (simulat-
ing the slightly acidic tumor pH) are given in Fig.  3. At 
pH 7.4, only around ~ 20% of the bufalin cargo is released 
from the non-porous CS-PLGA NPs over 48  h. In con-
trast, the CS-pPLGA NPs gave a burst of drug release in 
the initial 4 h of the experiment, and reached a cumula-
tive release of 90.6 ± 4.5% after 12 h. This can be attrib-
uted to their porous structure. This burst release was 
inhibited after coating with the PLTM, which can be 
Fig. 2 DLS sizes of a CS‑pPLGA/Bu NPs and PLTM‑CS‑pPLGA/Bu NPs in water; b PLTM‑CS‑pPLGA/Bu NPs in different solutions, including water, 
phosphate buffered saline (PBS) and 10% v/v serum‑containing DMEM cell culture medium. Data are presented as mean ± SD (n = 3)
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ascribed to the compact lipid bilayer at the exterior of the 
particles blocking bufalin release. The release of bufalin 
was much faster in the simulated acidic tumor environ-
ment (pH 5.5) than at pH 7.4. This is likely to be because 
the CS segments are more soluble under acidic condi-
tions, freeing their drug cargo as they dissolve [34]. Over-
all, it is clear that the PLTM-CS-pPLGA NPs can provide 
pH-dependent sustained release, and thus are potentially 
useful in the treatment of cancer.
MTT assay
The cytocompatibility of the blank PLTM-CS-pPLGA 
NPs with H22 cells was investigated using the MTT 
assay (Fig. 4a). No in vitro toxicity was observed for the 
nanoparticles even when the concentration reached 
500  μg/mL. The carrier can thus be regarded as having 
good cytocompatibility. The PLTM-CS-pPLGA/Bu NPs 
have clear toxicity to H22 cells (Fig.  4b), and are more 
potent than free bufalin in this regard. When the bufa-
lin concentration is raised to 20 μg/mL, the cell viability 
declines to 43.0%, 34.2% and 17.9% with free bufalin, the 
CS-pPLGA/Bu NPs and PLTM-CS pPLGA NPs, respec-
tively. Similar trends are seen at the other concentrations 
studied: the PLTM coating clearly enhances the efficacy 
of the formulation. This may be attributed to efficient 
internalization mediated by the targeted binding of 
P-selectin on the surface of PLTM to CD44 receptors of 
H22 cells.
Cellular uptake of nanoparticles
The cellular uptake of FITC-CS-pPLGA or FITC-PLTM-
CS-pPLGA NPs was probed by CLSM. As shown in 
Fig.  5, H22 cells treated with FITC labeled PLTM-CS-
pPLGA NPs exhibited strong intracellular fluorescence 
intensity. In contrast, only weak fluorescence intensity 
localized inside or around the cellular membranes was 
seen when H22 cells were treated with FITC-CS-pPLGA 
NPs: the NPs appeared unable to reach the nuclei of H22 
cells. To further evaluate the endocytosis mechanism of 
cellular uptake, a blocking experiment was performed in 
which the H22 cells were pre-treated with free P-selectin. 
CLSM (Fig.  5) showed that the fluorescence signals in 
free P-selectin pre-incubated H22 cells were significantly 
reduced. In accordance, flow cytometry (Fig.  6) dem-
onstrated that the cellular uptake of FITC-PLTM-CS-
pPLGA NPs by H22 cells was about 7.4-fold greater than 
uptake of FITC-CS-pPLGA NPs. The cellular uptake was, 
Fig. 3 In vitro drug release profiles of CS‑PLGA, CS‑pPLGA, and 
PLTM‑CS‑pPLGA NPs. Data are presented as mean ± SD (n = 3)
Fig. 4 MTT viability results for a H22 cells treated with blank PLTM‑CS‑pPLGA NPs, b H22 cells treated with free bufalin, CS‑pPLGA/Bu and 
PLTM‑CS‑pPLGA/Bu NPs
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however, significantly reduced by pre-incubated H22 
cells with free P-selectin. These results indicate that the 
biomimetic membrane can enhance internalization by 
cancerous cells, presumably attributed to the binding of 
P-selectin on the PLTM to CD44 receptors of H22 cells. 
The CLSM results for RAW 264.7 cells treated with 
FITC-PLTM-CS-pPLGA NPs are rather different to those 
obtained with H22 cells (Additional file  1: Figure S7). 
The NPs are mainly located around the cell membranes, 
demonstrating that the biomimetic nanoparticles con-
tained “self-recognized” proteins (CD47). These inher-
ently mimic the surface properties of the host cells and 
thus can escape uptake by macrophages and send “don’t 
eat me” signals to the host [22].
Hemocompatibility assay
A hemolysis assay was performed to evaluate the bio-
compatibility of PLTM-CS-pPLGA NPs with RBCs. 
Microscopic observations (Additional file  1: Figure S8) 
showed that no morphological changes and no signifi-
cant lysis were observed after RBCs were treated with a 
high concentration of PLTM-CS-pPLGA NPs (500  μg/
mL). The amount of hemoglobin released from RBCs into 
solution permits the degree of hemolysis to be quanti-
fied: spectroscopic results showed only ~ 3.85% RBC lysis 
(Additional file 1: Table S2). The results indicated that the 
PLTM-CS-pPLGA NPs are blood-compatible biomateri-
als according to the ISO/TR 7406 standard [35].
In vivo biodistribution in H22 tumor‑bearing mice
In vivo and ex  vivo fluorescence imaging was used to 
evaluate the tumor targeting capability of Cy5.5 labeled 
PLTM-CS-pPLGA NPs and Cy5.5 labeled CS-pPLGA 
NPs. Strong fluorescence signals were observed at the 
tumor site 6 h after injection of the PLTM-CS-pPLGA 
NPs (Fig.  7a), demonstrating the targeting ability of 
the biomimetic nanoparticles. Elevated fluorescence 
intensity was also found at the tumor site even at 24 h 
post injection. After 6  h imaging, one mouse was sac-
rificed and the tumor and major organs harvested 
for ex  vivo imaging. The fluorescence intensity at the 
tumor site was much higher than in the other organs 
Fig. 5 CLSM images of H22 cells following 2 h incubation with FITC‑CS‑pPLGA, FITC‑PLTM‑CS‑pPLGA NPs, after a 1 h pre‑treatment with or without 
free P‑selectin. Scale bar: 20 μm
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(Fig.  7b), indicating that PLTM-CS-pPLGA NPs have 
good tumor selectivity. The results were confirmed by 
quantitative region-of-interest (ROI) analysis (Fig.  7c), 
which showed 1.15-fold and 3.12-fold high fluorescence 
intensity in the tumor than in the liver and kidney 
respectively.
In contrast, low fluorescence signals were observed at 
the tumor site for the uncoated Cy5.5 labeled CS-pPLGA 
NPs during whole treatment time (Additional file 1: Fig-
ure S9a). Ex vivo imaging results (Additional file 1: Figure 
S9b) showed weaker fluorescence signals in the tumor 
tissue, but stronger fluorescence in the liver and kidney. 
Quantitative ROI analysis result (Additional file  1: Fig-
ure S9c) showed the fluorescence intensity in the liver 
and kidney were 6.2-fold and 3.2-fold higher than that 
in tumor respectively. Collectively, these in vivo findings 
confirm that the nanoparticles coated with the PLTM 
could inhibit uptake by the reticuloendothelial system 
and achieve active targeting to the tumor.
Immunofluorescence assay
Immunofluorescence assay was subjected to evaluate the 
targeting ability of PLTM biomimetic NPs on the histo-
logical level. As shown in Fig. 8, strong red fluorescence 
of Cy5.5-labeled PLTM-CS-pPLGA/Bu NPs could be 
observed in tumor tissues, while tumor tissues treated 
with Cy5.5-labeled CS-pPLGA/Bu NPs exhibited weak 
red fluorescence. The results demonstrated that PLTM 
would drive the NPs to specifically bind to tumor cells, 
which attributing to the binding of P-selectin on the 
PLTM to CD44 receptors of H22 cells.
In vivo antitumor efficacy
The in  vivo antitumor efficacy was then assessed using 
H22 tumor-bearing ICR mice. The results (Fig.  9) 
Fig. 6 Flow cytometry data for: a untreated H22 cells; H22 cells incubated for 4 h with FITC‑labeled b CS‑pPLGA NPs or c PLTM‑CS‑pPLGA NPs; and, 
d cells pre‑incubated with P‑selectin for 1 h before being exposed to FITC‑PLTM‑CS‑pPLGA NPs for 4 h, and e corresponding quantified fluorescence 
intensity
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revealed that continuous tumor progression was wit-
nessed for the mice treated with PBS and free bufalin, 
likely owing to the insufficient tumor retention of free 
bufalin. This manifested in a rapid growth in tumor vol-
ume over the 16 days of the experiment (Fig. 9a–c). For 
mice treated with CS-pPLGA/Bu NPs, tumor growth was 
significantly inhibited, and for animals receiving PLTM-
CS-pPLGA/Bu NPs, the tumors showed the slowest 
growth and smallest volume at the end of the treatment. 
When the mice were treated with PBS, a continuous 
increase in body weight was noted (Fig. 9d) as a result of 
the increasing tumor size. The mice treated with other 
bufalin formulations showed no such increase, with no 
noticeable change in body weight. This indicates that the 
drug and nanoparticles had low systemic toxicity.
In addition, in  situ TUNEL assay results (Fig.  10) 
showed no green coloration in the tumors of mice treated 
with PBS, indicating the cells all to be viable. Some 
green-colored cells are noticeable with all the bufalin 
treatments, indicative of apoptosis. The highest levels of 
apoptosis were seen in the tumors resected from mice 
treated with PLTM-CS-pPLGA/Bu NPs, as is clear from 
the increased number of green-colored cells. Therefore, 
the PLTM cloaked drug-loaded nanoparticles induce 
Fig. 7 a Time‑dependent in vivo fluorescence imaging of Cy5.5 labeled PLTM‑CS‑pPLGA NPs in H22 tumor‑bearing ICR mice. b Ex vivo fluorescence 
imaging of the excised tumors and normal organs at 6 h post‑injection. c ROI analysis of fluorescent intensities from the tumor and major organs. 
Error bars indicate SD (n = 3)
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Fig. 8 Localization of NPs in H22 bearing tumor tissues. Mice bearing H22 tumor were intravenously injected with Cy5.5‑labeled CS‑pPLGA/Bu NPs 
and Cy5.5‑labeled PLTM‑CS‑pPLGA/Bu NPs. 24 h later, the tumors were removed and sectioned under frozen conditions followed by staining with 
an antibody against CD44 (green). The nuclei of cells were visualized using DAPI (blue)
Fig. 9 In vivo antitumor efficacy of different bufalin formulations in H22‑tumor bearing ICR mice. a H22 tumor growth curves after intravenous 
injection the formulations. Error bars indicate SD (n = 5). b Representative images of tumors isolated after treatment for 16 days (1: PBS; 2: free 
bufalin; 3: CS‑pPLGA/Bu NPs; 4: PLTM‑CS‑pPLGA/Bu NPs). c Mean weights of the H22 tumors isolated on day 16. d Body weight changes over the 
16 days of the experiment (mean ± SD, n = 5)
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apoptosis more effectively than either free bufalin or the 
naked NPs.
Off-target toxicity is always a concern with cancer ther-
apies. Histological analyses of major organs post-sacrifice 
were thus conducted (Additional file 1: Figure S10). The 
images obtained from untreated mice and the PLTM-CS-
pPLGA/Bu NPs are very similar, and hence it is clear that 
the NPs do not cause any significant systemic toxicity.
Biosafety in vivo
To investigate the feasibility of the PLTM biomimetic 
CS-pPLGA NPs for clinical translation, we further evalu-
ated the biosafety in vivo. H22-tumor bearing ICR mice 
were i.v. injected with PBS or PLTM-CS-pPLGA NPs. No 
death or discomfort was observed during the experiment. 
The mice treated with PLTM-CS-pPLGA NPs showed 
no significant tumor volume difference compared to the 
control group (Additional file 1: Figure S11a), indicating 
that the PLTM biomimetic NPs can’t cause tumor growth 
inhibition. Histology analysis of the liver and kidney 
(Additional file 1: Figure S11b) showed no inflammation 
or lesions. The sections from NP-treated mice are very 
similar to the negative control group, indicating that the 
NPs do not cause systemic toxicity.
As shown in Additional file  1: Figure S11c and 11d, 
hepatic function markers (ALT and AST) and renal 
function markers (CREA and BUN) were determined to 
be normal and again very similar to the control group, 
suggesting no obvious hepatic or kidney disorders were 
induced by the PLTM-CS-pPLGA NPs in  vivo. Col-
lectively, these results demonstrated that the repeated 
administration of the PLTM cloaked NPs has a low risk of 
off-target toxicity.
Compared to other PLGA-based nanoscale deliv-
ery systems, the PLTM-modified materials prepared in 
this work have a number of advantages. For example, 
Xu et  al. [36] aimed to improve the biocompatibility of 
PLGA by modifying it with poly(ethylene glycol) (PEG); 
they prepared a monomethoxy poly(ethylene glycol)-
b-PLGA-b-poly(l-glutamic acid) (mPEG-PLGA-PGlu) 
nanoparticles. Although the PEG segment improved the 
formulation’s biocompatibility, the synthetic procedure 
was complicated and did not allow for any active target-
ing. Other biomimetic delivery systems, for example red 
blood cell membrane (RBCM) cloaked nanoparticles 
[17], have excellent biocompatibility, low immunogenic-
ity and prolonged circulation times in vivo and have been 
suggested to have enhanced anti-tumor efficacy. How-
ever, the lack of active targeting to tumor cells by the 
RBCM limits its use for preparing biomimetic cancer 
therapeutics. The use of the PLTM overcomes this issue, 
and provides enhanced efficacy through specific binding 
of P-selectin to the CD44 receptors overexpressed on the 
surface of H22 cells.
Conclusions
In this study, we developed platelet membrane (PLTM)-
functionalized porous nanoparticles (NPs) which per-
mit active-targeting mediated delivery of bufalin to 
tumor sites. These nanoparticles comprised a PLGA-
chitosan conjugate, and were able to achieve a bufalin 
loading of ~ 8.5%. The PLTM coating led to particles 
providing pH-dependent sustained drug release over 
2 days. The carrier was found to be biocompatible with 
H22 cells, while the drug-loaded analogue could effec-
tively kill cancer cells in  vitro. A high level of uptake 
of PLTM-coated NPs by cancer cells was observed by 
confocal microscopy and flow cytometry analysis. 
In vivo imaging showed accumulation of the NPs in the 
tumor site, demonstrating their active targeting ability 
as a result of targeted binding of P-selectin to the CD44 
receptors overexpressed on the surface of H22 cells. 
The PLTM-coated NPs were also found to be effective 
in reducing tumor growth in  vivo, and did not cause 
off-target effects on the major organs. Therefore, the 
novel PLTM biomimetic formulations reported in this 
work have significant potential as anti-cancer drug car-
riers. Furthermore, platelets have the ability to selective 
adhere to injured blood vessels [37], so the PLTM-
coated material could also be used to deliver vascular 
Fig. 10 TUNEL‑stained images of tumor slices taken from the various treatment groups
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disrupting agents or combined with photothermal 
therapy [38] to damage tumor blood vessels, and thus 
achieve enhanced anti-tumor activity.
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aqueous media at pH 5.0, 7.4, and 8.6. Figure S3.  N2 adsorption/desorp‑
tion isotherms of CS‑pPLGA NPs and the corresponding pore‑size distribu‑
tion curves (inset). Figure S4. (A) A digital photograph taken during the 
isolation of PLTs from plasma, and bright field microscopy images of (B) 
PLTs and (C) RBCs. Figure S5. Zeta potential values of PLTM, CS‑pPLGA 
and PLTM‑CS‑pPLGA NPs at pH=7.4. Figure S6. Western blotting results 
for key platelet membrane protein bands. Figure S7. CLSM images of 
RAW 264.7 cells following 2 h incubation with PLTM‑CS‑pPLGA NPs. Scale 
bar: 20 μm. Figure S8. Microscope images of RBCs incubated with (a) 
PLTM‑CS‑pPLGA NPs, (b) PBS (negative control), (c) Triton X‑100 (positive 
control), and corresponding pictures after centrifugation (5000 rpm, 
10 min). RBCs precipitate indicated no hemolysis. Figure S9. (a) Time‑
dependent in vivo fluorescence imaging of Cy5.5 labeled CS‑pPLGA NPs 
in H22 tumor‑bearing ICR mice. (b) Ex vivo fluorescence imaging of the 
excised tumors and normal organs at 6 h post‑injection. (c) ROI analysis 
of fluorescent intensities from the tumor and major organs. Error bars 
indicate S.D. (n = 3). Figure S10. H&E stained images of the major organs 
collected from (I) untreated mice and (II) mice treated for 16 days with 
PLTM‑CS‑pPLGA/Bu NPs. Figure S11. (a) H22‑tumor bearing mice tumor 
mass changes over 16 days (mean ± S.D., n = 5); (b) histological analyses 
of the liver and kidney of mice following 16 days’ treatment with PBS 
and PLTM‑CS‑pPLGA NPs (scale bar: 50 μm); (c) and (d) blood biochemi‑
cal analyses of the mice treated with PBS or the PLTM‑CS‑pPLGA NPs. 
Table S1. Encapsulation efficiency and loading content of NPs prepared 
under different CS‑PLGA/Bu (w/w) ratio (mean ± SD, n = 3). Table S2. 
Hemocompatibility data. Each number indicating the average of three 
times spectroscopic measurements.
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